全文获取类型
收费全文 | 5633篇 |
免费 | 265篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 340篇 |
妇产科学 | 68篇 |
基础医学 | 653篇 |
口腔科学 | 154篇 |
临床医学 | 427篇 |
内科学 | 1104篇 |
皮肤病学 | 257篇 |
神经病学 | 286篇 |
特种医学 | 117篇 |
外科学 | 838篇 |
综合类 | 117篇 |
一般理论 | 2篇 |
预防医学 | 245篇 |
眼科学 | 276篇 |
药学 | 604篇 |
1篇 | |
中国医学 | 36篇 |
肿瘤学 | 367篇 |
出版年
2023年 | 27篇 |
2022年 | 91篇 |
2021年 | 196篇 |
2020年 | 91篇 |
2019年 | 116篇 |
2018年 | 130篇 |
2017年 | 86篇 |
2016年 | 138篇 |
2015年 | 173篇 |
2014年 | 209篇 |
2013年 | 294篇 |
2012年 | 413篇 |
2011年 | 442篇 |
2010年 | 235篇 |
2009年 | 200篇 |
2008年 | 353篇 |
2007年 | 360篇 |
2006年 | 324篇 |
2005年 | 326篇 |
2004年 | 342篇 |
2003年 | 288篇 |
2002年 | 239篇 |
2001年 | 73篇 |
2000年 | 63篇 |
1999年 | 67篇 |
1998年 | 80篇 |
1997年 | 36篇 |
1996年 | 30篇 |
1995年 | 39篇 |
1994年 | 29篇 |
1993年 | 27篇 |
1992年 | 44篇 |
1991年 | 37篇 |
1990年 | 32篇 |
1989年 | 33篇 |
1988年 | 20篇 |
1987年 | 24篇 |
1986年 | 19篇 |
1985年 | 15篇 |
1984年 | 21篇 |
1983年 | 11篇 |
1982年 | 18篇 |
1981年 | 18篇 |
1980年 | 18篇 |
1979年 | 14篇 |
1978年 | 20篇 |
1977年 | 12篇 |
1976年 | 10篇 |
1975年 | 7篇 |
1974年 | 8篇 |
排序方式: 共有5925条查询结果,搜索用时 703 毫秒
61.
Richard M Goldberg Daniel J Sargent Roscoe F Morton Charles S Fuchs Ramesh K Ramanathan Stephen K Williamson Brian P Findlay Henry C Pitot Steven R Alberts 《Journal of clinical oncology》2004,22(1):23-30
PURPOSE: Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin. In this study, we compared the activity and toxicity of three different two-drug combinations in patients with metastatic colorectal cancer who had not been treated previously for advanced disease. PATIENTS AND METHODS: Patients were concurrently randomly assigned to receive irinotecan and bolus fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus leucovorin (FOLFOX), or irinotecan and oxaliplatin (IROX). The primary end point was time to progression, with secondary end points of response rate, survival time, and toxicity. RESULTS: A total of 795 patients were randomly assigned between May 1999 and April 2001. A median time to progression of 8.7 months, response rate of 45%, and median survival time of 19.5 months were observed for FOLFOX. These results were significantly superior to those observed for IFL for all end points (6.9 months, 31%, and 15.0 months, respectively) or for IROX (6.5 months, 35%, and 17.4 months, respectively) for time to progression and response. The FOLFOX regimen had significantly lower rates of severe nausea, vomiting, diarrhea, febrile neutropenia, and dehydration. Sensory neuropathy and neutropenia were more common with the regimens containing oxaliplatin. CONCLUSION: The FOLFOX regimen of oxaliplatin and infused fluorouracil plus leucovorin was active and comparatively safe. It should be considered as a standard therapy for patients with advanced colorectal cancer. 相似文献
62.
Prahlad Duggal S. Chakravorty Ramesh K. Azad Chander Mohan 《Indian journal of otolaryngology and head and neck surgery》2006,58(4):349-351
Dacryocystorhinostomy is performed in patients with naso-lacrimal duct obstruction to bypass the site of obstruction so as
to relieve the patient of the irritating and socially embarrassing symptoms of epiphora. We discuss the various epidemiological
aspects especially the vast difference by which the females out-number the males in patients undergoing DCR and the likely
explanations for this difference in our study on 74 patients which underwent DCR in our institute. 相似文献
63.
Yeragani VK Pohl R Jampala VC Balon R Ramesh C Srinivasan K 《Depression and anxiety》2000,11(3):126-130
This study investigated beat-to-beat QT variability in patients with panic disorder before and after treatment with nortriptyline (n = 13) and paroxetine (n = 16), using an automated algorithm to compute QT intervals. An increase in QT variability appears to be associated with symptomatic patients with dilated cardiomyopathy and also with an increased risk for sudden cardiac death. QTvi (QT variability index: a log ratio of QT variance normalized for mean QT over heart rate variability normalized for mean heart rate) was significantly higher in supine posture in patients with panic disorder treated with nortriptyline (P = 0.006) but not paroxetine. Thus paroxetine may be a better drug of choice especially in patients with coexisting cardiac disease. These findings are important especially in view of the recent reports of increased risk for cardiovascular mortality and sudden death in patients with anxiety and depression. QTvi can be a valuable noninvasive measure of temporal repolarization lability, especially to study the side effects of medications which affect cardiac autonomic function. 相似文献
64.
Ravikanth Bhamidipati P Venkatesh Prajakta V Dravid Prasad C Narasimhulu Sastry Tvrs Jagattaran Das Ramesh Mullangi Nuggehally R Srinivas 《European journal of drug metabolism and pharmacokinetics》2005,30(3):187-193
The aim of this study was to determine the bioavailability of a novel oxazolidinone, DRF-6196, in mice and rats following intravenous (i.v) and oral dosing and to compare the pharmacokinetics with those obtained following linezolid dosing. Blood samples were drawn at predetermined intervals up to 24 h post-dose after either DRF-6196 or linezolid administration. The concentrations of DRF-6196 and linezolid in various plasma samples were determined by a HPLC method. Following oral administration maximum concentrations of DRF-6196 were achieved within 0.5 h irrespective of the species. While the doses increased in the ratio of 1 : 3 : 10, mean Cmax and AUC(0-infinity) values in mice for DRF-6196 increased in the ratio of 1 : 3.87 : 8.53 and 1 : 2.51 : 9.24, respectively. Both the Cmax and AUC(0-infinity) values increased almost proportional to the dose administered in mice. Following i.v administration, the concentration of DRF-6196 declined in a bi-exponential fashion with terminal elimination half-life of 1.5 h irrespective of the species. The systemic clearance and volume of distribution of DRF-6196 in mice were 1.14 L/h/kg and 0.66 L/kg, respectively after i.v administration, while the respective values in rats were 0.61 L/h/kg and 0.41L/kg, respectively. Elimination half-life ranged between 0.8-1.5 h. Absolute oral bioavailability of DRF-6196 was found to be 80-96% across the test dose range. Although plasma levels of DRF-6196 were lesser compared to linezolid in the initial hours, it may not have any consequences on the clinical effectiveness of the molecule. 相似文献
65.
Mace L Rothenberg Bonnie LaFleur Donna E Levy Mary Kay Washington Sherry L Morgan-Meadows Ramesh K Ramanathan Jordan D Berlin Al B Benson Robert J Coffey 《Journal of clinical oncology》2005,23(36):9265-9274
PURPOSE: The clinical objective of this trial was to evaluate gefitinib in patients with metastatic colorectal cancer that had progressed despite prior treatment. Serial tumor biopsies were performed when possible and analyzed for activation of the epidermal growth factor receptor (EGFR) signaling pathway. Serial serum samples were measured for amphiregulin and transforming growth factor-alpha (TGFalpha). PATIENTS AND METHODS: One hundred fifteen patients were randomly assigned to receive gefitinib 250 or 500 mg orally once a day. One hundred ten patients were assessable for clinical efficacy. Biologic evaluation was performed on paired tumor samples from 28 patients and correlated with clinical outcome. RESULTS: Median progression-free survival was 1.9 months (95% CI, 1.8 to 2.1 months) and 4-month progression-free survival rate was 13% +/- 5%. One patient achieved a radiographic partial response (RR = 1%; 95% CI, 0.01% to 5%). Median survival was 6.3 months (95% CI, 5.1 to 8.2 months). The most common adverse events were skin rash, diarrhea, and fatigue. In the biopsy cohort, expression of total or activated EGFR, activated Akt, activated MAP-kinase, or Ki67 did not decrease following 1 week of gefitinib. However, a trend toward decreased post-treatment levels of activated Akt and Ki67 was observed in patients with a PFS higher than the median, although these did not reach the .05 level of significance. CONCLUSION: Gefitinib is inactive as a single agent in patients with previously treated colorectal cancer. In tumor samples, gefitinib did not inhibit activation of its proximal target, EGFR. Trends were observed for inhibition of downstream regulators of cellular survival and proliferation in patients achieving longer progression-free survival. 相似文献
66.
Manthena V.S. Varma Ramesh Panchagnula 《European journal of pharmaceutical sciences》2005,25(4-5):445-453
Solubility and permeability being important determinants of oral drug absorption, this study was aimed to investigate the effect of d--tocopheryl polyethylene glycol 1000 succinate (TPGS) on the solubility and intestinal permeability of paclitaxel in vitro, in situ and in vivo, in order to estimate the absorption enhancement ability of TPGS. Aqueous solubility of paclitaxel is significantly enhanced by TPGS, where a linear increase was demonstrated above a TPGS concentration of 0.1 mg/ml. Paclitaxel demonstrated asymmetric transport across rat ileum with significantly greater (26-fold) basolateral-to-apical (B–A) permeability than that in apical-to-basolateral (A–B) direction. Presence of P-glycoprotein (P-gp) inhibitor, verapamil (200 μM), diminished asymmetric transport of paclitaxel suggesting the role of P-gp-mediated efflux. TPGS showed a concentration-dependent increase in A–B permeability and decreased B–A permeability. The maximum efflux inhibition activity was found at a minimum TPGS concentration of 0.1 mg/ml, however, further increase in TPGS concentration resulted in decreased A–B permeability with no change in B–A permeability. Thus, the maximum paclitaxel permeability attained with 0.1 mg/ml TPGS was attributed to the interplay between TPGS concentration dependent P-gp inhibition activity and miceller formation. In situ permeability studies in rats also demonstrated the role of efflux in limiting permeability of paclitaxel and inhibitory efficiency of TPGS. The plasma concentration of [14C]paclitaxel following oral administration (25 mg/kg) was significantly increased by coadministration of TPGS at a dose of 50 mg/kg in rats. Bioavailability is enhanced about 4.2- and 6.3-fold when [14C]paclitaxel was administrated with verapamil (25 mg/kg) and TPGS, respectively, as compared to [14C]paclitaxel administered alone. The effect of verapamil on oral bioavailability of [14C]paclitaxel was limited relative to the TPGS, consistent with the in vitro solubility and permeability enhancement ability of TPGS. In conclusion, the current data suggests that the coadministration of TPGS may improve the bioavailability of BCS class II–IV drugs with low solubility and/or less permeable as a result of significant P-gp-mediated efflux. 相似文献
67.
Kawasaki disease and giant coronary artery aneurysms: the role of echocardiography from diagnosis through follow‐up
下载免费PDF全文
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Adam C. Adler M.D. M.S. Ramesh Kodavatiganti M.D. 《Echocardiography (Mount Kisco, N.Y.)》2016,33(8):1245-1250
Kawasaki disease is an acquired vasculitis that can affect the coronary arteries placing the patient at risk for coronary artery thrombosis, myocardial ischemia and infarction. The risk of complications related to coronary artery involvement persists for years despite recovery from the acute illness phase. The risk of late coronary disease progression necessitates long term follow‐up generally accomplished by non‐invasive echocardiography in pediatric patients. We review the utility of echocardiography in patients with Kawasaki disease as it relates to initial management, risk stratification and follow‐up of these children. 相似文献
68.
69.
Endoscopic ultrasonography is not required for staging malignant esophageal strictures that preclude the passage of a diagnostic gastroscope
下载免费PDF全文
![点击此处可从《Digestive endoscopy》网站下载免费的PDF全文](/ch/ext_images/free.gif)
70.